Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 January 2017Website:
http://www.panbela.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PBLA Latest News
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics Second Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET with Company Representatives James Carbonara - IR, HaydenIR, Jennifer Simpson - President & CEO, and Susan Horvath - CFO. Conference Call Participants include Jonathan Aschoff from Roth Capital Partners. Operator greets attendees and introduces the call.
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
Panbela Therapeutics (NASDAQ: PBLA ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed the pricing of a public offering for its shares. Panbela Therapeutics is selling 4,375,000 shares of its common stock for $2.06 each.
Shares of Panbela Therapeutics Inc. PBLA, +55.45% dropped 21.7% in premarket trading, as they paused after a two-day “meme”-like rally of 243.5%. The two-day rally in the biopharmaceutical company's stock, which followed a record-low close of 45.7 cents on Friday, was fueled by positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
Shares of Panbela Therapeutics Inc. skyrocketed again Tuesday, following positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants James Carbonara - IR Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
What type of business is Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
What sector is Panbela Therapeutics in?
Panbela Therapeutics is in the Healthcare sector
What industry is Panbela Therapeutics in?
Panbela Therapeutics is in the Biotechnology industry
What country is Panbela Therapeutics from?
Panbela Therapeutics is headquartered in United States
When did Panbela Therapeutics go public?
Panbela Therapeutics initial public offering (IPO) was on 03 January 2017
What is Panbela Therapeutics website?
https://www.panbela.com
Is Panbela Therapeutics in the S&P 500?
No, Panbela Therapeutics is not included in the S&P 500 index
Is Panbela Therapeutics in the NASDAQ 100?
No, Panbela Therapeutics is not included in the NASDAQ 100 index
Is Panbela Therapeutics in the Dow Jones?
No, Panbela Therapeutics is not included in the Dow Jones index
When was Panbela Therapeutics the previous earnings report?
No data
When does Panbela Therapeutics earnings report?
The next expected earnings date for Panbela Therapeutics is 08 November 2024